Inhibition of group IVA cytosolic phospholipase A2by thiazolyl ketones in vitro, ex vivo, and in vivo

Journal of Medicinal Chemistry

Volumn 57, Issue 18, 2014, Pages 7523-7535

  Kokotos, George ^a   Feuerherm, Astrid J ^b   Barbayianni, Efrosini ^a   Shah, Ishita ^c   Sæther, Mari ^b   Magrioti, Victoria ^a   Nguyen, Thuy ^b   Constantinou Kokotou, Violetta ^d   Dennis, Edward A ^c   Johansen, Berit ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 (BENZO[D]THIAZOL 2 YL) 2 (4 OCTYLPHENOXY)ETHANONE; 2 (4 FLUOROPHENOXY) 1 (THIAZOL 2 YL)ETHANONE; 2 (4 OCTYLPHENOXY) 1 (THIAZOL 2 YL)ETHANONE; 2 (BIPHENYL 4 YLOXY) 1 (THIAZOL 2 YL)ETHANONE; 2 PHENOXY 1 (THIAZOL 2 YL)ETHANONE; ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; ETANERCEPT; ETHYL 2 [2 (DODECYLOXY)ACETYL]THIAZOLE 4 CARBOXYLATE; ETHYL 2 [2 [2 (4 OCTYLPHENOXY)ACETYL]THIAZOL 4 YL]ACETATE; ETHYL 2 [2 [2 (DODECYLOXY)ACETYL]THIAZOL 4 YL]ACETATE; KETONE DERIVATIVE; METHOTREXATE; METHYL 2 [2 (4 OCTYLPHENOXY)ACETYL]THIAZOLE 4 CARBOXYLATE; METHYL 2 [2 (4 OCTYLPHENOXY)ACETYL]THIAZOLE 4CARBOXYLATE; OLEIC ACID; PROSTAGLANDIN E2; THIAZOLYL KETONE DERIVATIVE; UNCLASSIFIED DRUG; COLLAGEN; KETONE; PHOSPHOLIPASE A2 GROUP IV; PLASMA PROTEIN; PLIALPHA; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROPHYLAXIS; SYNOVIOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; CYTOSOL; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; SECRETION (PROCESS); SYNOVIUM; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ARACHIDONIC ACID; ARTHRITIS; BLOOD PROTEINS; CELL LINE, TUMOR; COLLAGEN; CYTOSOL; DINOPROSTONE; DRUG DESIGN; GROUP IV PHOSPHOLIPASES A2; HUMANS; KETONES; MALE; MICE; OLEIC ACID; SYNOVIAL MEMBRANE; THIAZOLES;

EID: 84907487577     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500192s     Document Type: Article

References (60)

1. 2+-dependent translocation domain with homology to PKC and GAP Cell 1991, 65, 1043-1051
2. 2is a 100-kda protein in human monoblast U937 cells J. Biol. Chem. 1991, 266, 5268-5272
3. 2Biochemistry 1993, 32, 5935-5940
4. 2Nature 1997, 390, 622-625
5. 2in allergic response and parturition Nature 1997, 390, 618-622
6. 2α: hit to lead optimization J. Med. Chem. 2006, 49, 135-158
7. 2α J. Med. Chem. 2007, 50, 1380-1400
8. 2α: optimization of in vitro potency and rat pharmacokinetics for oral efficacy Bioorg. Med. Chem. 2008, 16, 1345-1358
9. 2α inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1 H -indol-3-yl]propyl} benzoic acid, Efipladib J. Med. Chem. 2008, 51, 3388-3413
10. A study comparing 4 dose regimens of PLA-695, Naproxen, and Placebo in subjects with osteoarthritis of the knee. http://clinicaltrials.gov/ct2/show/NCT00396955?term=NCT00396955&rank=1.
11. 2enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention Chem. Rev. 2011, 111, 6130-6185
12. 2research: from cells to animals to humans Prog. Lipid Res. 2011, 50, 152-192
13. 2family Prog. Lipid Res. 2006, 45, 487-510
14. 2inhibitors as potential therapeutic agents for the treatment of inflammatory diseases Expert Opin. Ther. Pat. 2010, 20, 1-18
15. 2inhibitors for the treatment of inflammatory diseases: a patent review (2010-present) Expert Opin. Ther. Pat. 2013, 23, 333-344
16. 2J. Med. Chem. 2000, 43, 1041-1044
17. Eno, K.; Okuno, T.; Nishi, K.; Murakami, Y.; Yamada, K.; Nakamoto, S.; Ono, T. Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone' Bioorg. Med. Chem. Lett. 2001, 11, 587-590
18. 2alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model Inflammation Res. 2010, 59, 53-62
19. 2α J. Med. Chem. 2006, 49, 2611-2620
20. 2α: bioisosteric replacement of the carboxylic acid and carboxamide moiety Bioorg. Med. Chem. 2007, 15, 2883-2891
21. 2α: synthesis, biological activity, metabolic stability, and solubility Bioorg. Med. Chem. 2008, 16, 3489-3500
22. 2α: effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability J. Med. Chem. 2010, 53, 8298-8308
23. 2α with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity J. Med. Chem. 2010, 53, 5165-5178
24. 2α: variation of the activated ketone moiety Bioorg. Med. Chem. Lett. 2011, 21, 1773-1776
25. 2α Br. J. Dermatol. 2012, 166, 306-316
26. Connolly, S.; Mete, A. Novel compounds. PCT Int. Appl. WO2000 034254.
27. 2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap Bioorg. Med. Chem. Lett. 2011, 21, 3128-3133
28. 2J. Med. Chem. 2002, 45, 2891-2893
29. 2by novel 2-oxoamides in vitro, in cells and in vivo J. Med. Chem. 2004, 47, 3615-3628
30. 2by 2-oxoamides J. Med. Chem. 2006, 49, 2821-2828
31. 2J. Med. Chem. 2007, 50, 4222-4235
32. 2enzymes Bioorg. Med. Chem. 2008, 16, 10257-10269
33. 2enzymes J. Med. Chem. 2008, 51, 8027-8037
34. 2J. Med. Chem. 2010, 53, 3602-3610
35. 2Bioorg. Med. Chem. 2013, 21, 5823-5829
36. 2determined by molecular dynamics and deuterium exchange mass spectrometry J. Am. Chem. Soc. 2009, 131, 8083-8091
37. 2through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics J. Am. Chem. Soc. 2013, 135, 1330-1337
38. 2reveals a novel topology and catalytic mechanism Cell 1999, 97, 349-360
39. Maryanoff, B. E.; Costanzo, M. J. Inhibitors of proteases and amide hydrolases that employ an α-ketoheterocycle as a key enabling functionality Bioorg. Med. Chem. 2008, 16, 1562-1595
40. 1subsite and its implications to structure-based drug design J. Med. Chem. 2005, 48, 1984-2008
41. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5044-5049
42. Dess, D. B.; Martin, J. C. A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species J. Am. Chem. Soc. 1991, 113, 7277-7287
43. Hantzsch, A.; Weber, J. H. Ueber verbindungen des thiazols (pyridins der thiophenreihe) Ber. Dtsch. Chem. Ges. 1887, 20, 3118-3132
44. Gaumont, A.-C.; Gulea, M.; Levillain, J. Overview of the chemistry of 2-thiazolines Chem. Rev. 2009, 109, 1371-1401
45. Williams, D. R.; Lowder, P. D.; Gu, Y.-G.; Brooks, D. A. Studies of mild dehydrogenations in heterocyclic systems Tetrahedron Lett. 1997, 38, 331-334
46. 2in mouse spleen and the macrophage cell line J774 Eur. J. Biochem. 1991, 202, 873-880
47. 2formation in mesangial cells Br. J. Pharmacol. 2012, 167, 1691-1701
48. 2types in biological samples by employing group-specific assays in the presence of inhibitors Prostaglandins Other Lipid Mediators 2005, 77, 235-248
49. 2modulates tumor necrosis factor-alpha- and interleukin-1beta-induced NF-kappa B activation J. Biol. Chem. 2001, 276, 30527-30536
50. Brand, D. D.; Latham, K. A.; Rosloniec, E. F. Collagen-induced arthritis Nat. Protoc. 2007, 2, 1269-1275
51. 2α-deficient mice are resistant to collagen-induced arthritis J. Exp. Med. 2003, 197, 1297-1302
52. Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis Ann. Rheum. Dis. 2008, 67, 1505-1515
53. 2exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis Arthritis Rheum. 2007, 56, 2608-2619
54. Sathisha, K. R.; Khanum, S. A.; Chandra, J. N. N. S.; Ayisha, F.; Balaji, S.; Marathe, G. K.; Gopal, S.; Rangappa, K. S. Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5h-[1,3,4]thiadiazolo[3,2- a ]pyrimidin-5-one derivatives Bioorg. Med. Chem. 2011, 19, 211-220
55. Beutner, G. L.; Kuethe, J. T.; Kim, M. M.; Yasuda, N. Expedient synthesis of 3-alkoxymethyl- and 3-aminomethyl-pyrazolo[3,4- b ]pyridines J. Org. Chem. 2009, 74, 789-794
56. 4analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo J. Med. Chem. 2004, 47, 2157-2165
57. Ozcan, S.; Kazi, A.; Marsilio, F.; Fang, B.; Guida, W. C.; Koomen, J.; Lawrence, H. R.; Sebti, S. M. Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors J. Med. Chem. 2013, 56, 3783-3805
58. Sommerfelt, R. M.; Feuerherm, A. J.; Jones, K.; Johansen, B. Cytosolic phospholipase A2 regulates TNF-induced production of joint destructive effectors in synoviocytes PLoS One 2013, 8, e83555
59. Wooley, P. H.; Luthra, H. S.; Stuart, J. M.; David, C. S. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates J. Exp. Med. 1981, 154, 688-700
60. Kim, S. H.; Kim, S.; Evans, C. H.; Ghivizzani, S. C.; Oligino, T.; Robbins, P. D. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4 J. Immunol. 2001, 166, 3499-3505